vs

Side-by-side financial comparison of Amarin Corp plc (AMRN) and REGIS CORP (RGS). Click either name above to swap in a different company.

REGIS CORP is the larger business by last-quarter revenue ($57.1M vs $45.1M, roughly 1.3× Amarin Corp plc). REGIS CORP runs the higher net margin — 0.8% vs -23.3%, a 24.1% gap on every dollar of revenue. On growth, REGIS CORP posted the faster year-over-year revenue change (22.3% vs 7.0%). Over the past eight quarters, REGIS CORP's revenue compounded faster (7.8% CAGR vs -18.3%).

Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid.

Regis Corporation is an American operator of hair salons. As of August 2021, it has 5,563 franchised and 276 company-owned salons. Its headquarters are in Minneapolis, Minnesota.

AMRN vs RGS — Head-to-Head

Bigger by revenue
RGS
RGS
1.3× larger
RGS
$57.1M
$45.1M
AMRN
Growing faster (revenue YoY)
RGS
RGS
+15.3% gap
RGS
22.3%
7.0%
AMRN
Higher net margin
RGS
RGS
24.1% more per $
RGS
0.8%
-23.3%
AMRN
Faster 2-yr revenue CAGR
RGS
RGS
Annualised
RGS
7.8%
-18.3%
AMRN

Income Statement — Q1 FY2026 vs Q2 FY2026

Metric
AMRN
AMRN
RGS
RGS
Revenue
$45.1M
$57.1M
Net Profit
$-10.5M
$456.0K
Gross Margin
Operating Margin
35.5%
10.8%
Net Margin
-23.3%
0.8%
Revenue YoY
7.0%
22.3%
Net Profit YoY
33.0%
-94.0%
EPS (diluted)
$0.16

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AMRN
AMRN
RGS
RGS
Q1 26
$45.1M
Q4 25
$49.2M
$57.1M
Q3 25
$49.7M
$59.0M
Q2 25
$72.7M
$60.4M
Q1 25
$42.0M
$57.0M
Q4 24
$62.3M
$46.7M
Q3 24
$42.3M
$46.1M
Q2 24
$67.5M
$49.4M
Net Profit
AMRN
AMRN
RGS
RGS
Q1 26
$-10.5M
Q4 25
$-1.2M
$456.0K
Q3 25
$-7.7M
$1.4M
Q2 25
$-14.1M
$116.5M
Q1 25
$-15.7M
$250.0K
Q4 24
$-48.6M
$7.6M
Q3 24
$-25.1M
$-853.0K
Q2 24
$1.5M
$91.2M
Gross Margin
AMRN
AMRN
RGS
RGS
Q1 26
Q4 25
47.1%
Q3 25
44.7%
Q2 25
69.2%
Q1 25
59.8%
Q4 24
-15.4%
Q3 24
38.5%
Q2 24
63.4%
Operating Margin
AMRN
AMRN
RGS
RGS
Q1 26
35.5%
Q4 25
-12.9%
10.8%
Q3 25
-22.4%
10.0%
Q2 25
-22.0%
12.1%
Q1 25
-39.9%
8.8%
Q4 24
-84.3%
11.8%
Q3 24
-59.5%
4.6%
Q2 24
-0.8%
Net Margin
AMRN
AMRN
RGS
RGS
Q1 26
-23.3%
Q4 25
-2.5%
0.8%
Q3 25
-15.6%
2.3%
Q2 25
-19.4%
192.9%
Q1 25
-37.4%
0.4%
Q4 24
-78.0%
16.4%
Q3 24
-59.4%
-1.9%
Q2 24
2.3%
184.7%
EPS (diluted)
AMRN
AMRN
RGS
RGS
Q1 26
Q4 25
$0.00
$0.16
Q3 25
$-0.02
$0.49
Q2 25
$-0.03
$43.67
Q1 25
$-0.04
$0.08
Q4 24
$-0.12
$2.71
Q3 24
$-0.06
$-0.36
Q2 24
$0.00
$38.40

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AMRN
AMRN
RGS
RGS
Cash + ST InvestmentsLiquidity on hand
$307.8M
$18.4M
Total DebtLower is stronger
$113.3M
Stockholders' EquityBook value
$188.7M
Total Assets
$645.8M
$588.3M
Debt / EquityLower = less leverage
0.60×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AMRN
AMRN
RGS
RGS
Q1 26
$307.8M
Q4 25
$302.6M
$18.4M
Q3 25
$286.6M
$16.6M
Q2 25
$298.7M
$17.0M
Q1 25
$281.8M
$13.3M
Q4 24
$294.2M
$10.2M
Q3 24
$305.7M
$6.3M
Q2 24
$306.7M
$10.1M
Total Debt
AMRN
AMRN
RGS
RGS
Q1 26
Q4 25
$113.3M
Q3 25
$111.3M
Q2 25
$110.8M
Q1 25
$112.0M
Q4 24
$111.5M
Q3 24
$95.2M
Q2 24
$99.5M
Stockholders' Equity
AMRN
AMRN
RGS
RGS
Q1 26
Q4 25
$459.3M
$188.7M
Q3 25
$458.9M
$187.6M
Q2 25
$464.9M
$185.6M
Q1 25
$473.7M
$68.6M
Q4 24
$486.2M
$66.7M
Q3 24
$531.4M
$56.4M
Q2 24
$551.9M
$56.8M
Total Assets
AMRN
AMRN
RGS
RGS
Q1 26
$645.8M
Q4 25
$670.8M
$588.3M
Q3 25
$659.8M
$592.1M
Q2 25
$670.1M
$599.0M
Q1 25
$655.7M
$511.2M
Q4 24
$685.3M
$530.1M
Q3 24
$750.6M
$508.9M
Q2 24
$799.9M
$530.5M
Debt / Equity
AMRN
AMRN
RGS
RGS
Q1 26
Q4 25
0.60×
Q3 25
0.59×
Q2 25
0.60×
Q1 25
1.63×
Q4 24
1.67×
Q3 24
1.69×
Q2 24
1.75×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AMRN
AMRN
RGS
RGS
Operating Cash FlowLast quarter
$1.7M
Free Cash FlowOCF − Capex
$891.0K
FCF MarginFCF / Revenue
1.6%
Capex IntensityCapex / Revenue
1.4%
Cash ConversionOCF / Net Profit
3.65×
TTM Free Cash FlowTrailing 4 quarters
$14.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AMRN
AMRN
RGS
RGS
Q1 26
Q4 25
$15.3M
$1.7M
Q3 25
$-12.7M
$2.3M
Q2 25
$16.6M
$6.8M
Q1 25
$-12.5M
$6.2M
Q4 24
$-13.3M
$2.1M
Q3 24
$-2.4M
$-1.3M
Q2 24
$-2.7M
$5.1M
Free Cash Flow
AMRN
AMRN
RGS
RGS
Q1 26
Q4 25
$891.0K
Q3 25
$1.9M
Q2 25
$6.2M
Q1 25
$5.9M
Q4 24
$1.7M
Q3 24
$-1.4M
Q2 24
$5.1M
FCF Margin
AMRN
AMRN
RGS
RGS
Q1 26
Q4 25
1.6%
Q3 25
3.2%
Q2 25
10.3%
Q1 25
10.3%
Q4 24
3.6%
Q3 24
-3.0%
Q2 24
10.3%
Capex Intensity
AMRN
AMRN
RGS
RGS
Q1 26
Q4 25
1.4%
Q3 25
0.7%
Q2 25
0.9%
Q1 25
0.6%
Q4 24
0.9%
Q3 24
0.0%
Q2 24
0.0%
Cash Conversion
AMRN
AMRN
RGS
RGS
Q1 26
Q4 25
3.65×
Q3 25
1.68×
Q2 25
0.06×
Q1 25
24.80×
Q4 24
0.28×
Q3 24
Q2 24
-1.81×
0.06×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AMRN
AMRN

U.S$35.6M79%
Europe$4.9M11%
Rest-of-World (ROW)$2.8M6%
Licensing & Royalties$1.8M4%

RGS
RGS

Franchise Segment$37.9M66%
Royalty$13.6M24%
Other$2.8M5%
Fees$1.8M3%
Franchise Fees$1.0M2%

Related Comparisons